patient view

This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.

drug · small molecule

save

PROSCAR

Marketedupdated 2mo ago

/ fi-NA-stə-RYDE /

by $OGN Organon & Co.🔗 ChEMBL

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 6 investigational indications.

targets

3-oxo-5-alpha-steroid 4-dehydrogenase 2

all catalysts(41)

approval · 41

view all 41 catalysts →

News(0)

no news has mentioned this drug yet

brand

PROSCAR

trade names

Aindeem, Finasteride, Finasteride component of entadfi, Propecia, Proscar, Prostide

generic

FINASTERIDE

MOA

12.1 Mechanism of Action The development and enlargement of the prostate gland is dependent on the potent androgen, 5α-dihydrotestosterone (DHT). Type II 5α-reductase metabolizes testosterone to DHT in the prostate gland, liver and skin. DHT induces androgenic effects by binding to androgen receptors in the cell nuclei of these organs. Finasteride is a competitive and specific inhibitor of Type II 5α-reductase with which it slowly forms a stable enzyme complex. Turnover from this complex is extremely slow (t ½ ~ 30 days). This has been demonstrated both in vivo and in vitro . Finasteride has no affinity for the androgen receptor. In man, the 5α-reduced steroid metabolites in blood and urine are decreased after administration of finasteride.

phase

marketed

PROSCAR

targets

all catalysts(41)

News(0)

comments(0)

Report a data issue

🐶 often sniffed alongside

Trials studying PROSCAR